VAL to debut at INTERPHEX 2026 with live demonstrations and pilot opportunities for life sciences companies
SANTA CLARA, Calif., April 14, 2026 ― ValGenesis, the market leader in digital validation lifecycle management, today announced the launch of the next generation of VAL™ (ValGenesis AI), designed to help life sciences companies streamline and accelerate validation activities across the lifecycle through governed, human-led workflows within the ValGenesis digital validation platform. The next generation of VAL will debut at INTERPHEX, April 21–23, at the Javits Center in New York City, and open a limited pilot program for qualified life sciences companies.
Validation in life sciences is a complex, document-intensive process spanning authoring, trace generation, assessment, execution, and post-execution review. These activities often depend on specialized expertise and manual effort, which can introduce variability, rework, and delays. VAL helps teams work faster and more consistently by supporting protocol and trace generation, gap assessment, execution review, evidence analysis, and anomaly identification within defined workflows, while preserving human review, traceability, and control.
VAL empowers life sciences companies to apply artificial intelligence with confidence by using their own approved validation documents, enterprise data, policies and procedures, and applicable regulatory guidance as trusted guardrails across the full validation lifecycle. Grounded in approved content and customer-specific domain knowledge, VAL delivers accurate, context-aware support to accelerate document generation, strengthen gap assessment against internal and regulatory expectations, and assist with validation execution within a governed environment designed for GxP compliance, auditability, and human-led decision-making.
As life sciences companies evaluate how to apply AI in regulated environments, ValGenesis is advancing a practical and responsible model for adoption. Unlike general-purpose AI tools, VAL operates within governed workflows within digital validation systems, where human oversight, procedural controls, and regulatory traceability remain central. This enables life sciences organizations to apply AI in a controlled, scalable manner while keeping critical decisions in the hands of qualified personnel. With AI embedded across the validation lifecycle, life sciences companies can achieve up to an 80% reduction in validation time and cost compared with manual processes and deliver at least 50% greater efficiency than conventional digital validation.
“Life sciences companies want to realize the value of AI, but they must do so in a way that strengthens control, consistency, and confidence in GxP environments,” said Siva Samy, CEO and Chief Product Strategist at ValGenesis. “VAL was designed specifically for that reality. It helps validation teams move faster and work smarter by placing AI inside governed GxP workflows, where human expertise remains in control and compliance remains foundational.”
At INTERPHEX 2026, ValGenesis subject matter experts will host two educational sessions, and company executives will be on-site to meet with customers, partners, and industry stakeholders. Attendees will have the opportunity to experience live demonstrations of VAL and the broader ValGenesis platform and learn how to participate in VAL AI pilot programs.
Members of the media and industry analysts are invited to schedule briefings with ValGenesis executives during the event.
Visit ValGenesis at booth 3552 to see VAL in action.
ABOUT VALGENESIS INC.
ValGenesis, Inc. is the global leader in enterprise digital validation. For nearly two decades, ValGenesis has helped life sciences companies digitize commissioning, qualification, and validation processes through its AI-enabled ValGenesis Smart GxP™ Platform, which includes solutions for risk management, cleaning validation, continued process verification, and CMC development. ValGenesis helps customers accelerate delivery, strengthen compliance, and improve operational efficiency across the product lifecycle. For more information, visit www.valgenesis.com.
For more information, contact:
Erin Farrell-Talbot, Farrell-Talbot Consulting, 917-232-9309, erin@farrelltalbot.com